LEON-nanodrugs GmbH Advances Nanoparticle Drug Delivery Manufacturing with CMAC Collaboration

In a milestone for nanoparticle drug delivery technology, leon-nanodrugs GmbH (LEON), based in Munich, Germany, has unveiled groundbreaking results from a technical evaluation conducted in cooperation with CMAC, University of Strathclyde. This collaboration, leveraging the expertise of Professor Yvonne Perrie's team at CMAC and LEON's scientific team, focused on testing LEON's innovative FR-JET formulation technology, aimed at revolutionising nanoparticle manufacturing for pharmaceutical applications.

Amid growing interest in the pharmaceutical industry for lipid nanoparticles (LNP) due to their potential in targeted drug delivery, gene therapy, and vaccine development, LEON's FR-JET technology emerges as a solution to existing production challenges. The technology facilitates the scalable, efficient, and GMP-compliant production of LNPs, a critical advancement given the limitations of current production methods. The evaluation confirmed the FR-JET technology's ability to reduce scaling risks and achieve higher process concentrations, with produced LNP models showing promising results in both in-vitro and in-vivo tests.

This collaboration underscores the significance of partnerships in fostering innovation and tackling complex healthcare challenges. Both LEON and CMAC emphasize the critical impact of this technology on pharmaceutical manufacturing, particularly in the economic production of individual batches, marking a significant step forward in medicine manufacturing and delivery.